On the other hand, the combined analysis of antibodies to p53, HER-2 (Human Epidermal growth factor Receptor-2), IGFBP-2 (Insulin like Growth Factor Binding Protein 2), and TOPO2α (Topoisomerase-2-alpha) increased both diagnostic specificity and sensitivity to up to 75% for breast cancer patients [12]. The gene discussed is TP53; the disease is breast carcinoma.